Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 1;159(5):560-563.
doi: 10.1001/jamadermatol.2023.0175.

Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus

Katharina Shaw  1 , Stephanie Sanchez-Melendez  1 , Dustin Taylor  1 , Julia Barker  2 , Avery LaChance  1 , Neda Shahriari  1 , Ruth Ann Vleugels  1
Affiliations

Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus

Katharina Shaw et al. JAMA Dermatol. .
No abstract available

Plain language summary

This case series examines the efficacy of anifrolumab as a therapeutic option for patients with lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr LaChance reported grants from Pfizer outside the submitted work. Dr Vleugels reported grants from Pfizer PI outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Representative Clinical Images Before and After 2 Months of Treatment With Anifrolumab
A woman in her 40s with a history of long-standing DLE on chronic prednisone (10 mg daily) with extensive erythematous, scaly plaques with peripheral hyperpigmentation involving the face, scalp (A), extremities (B), and chest (C). Her disease had previously proven refractory to hydroxychloroquine, mycophenolate mofetil, methotrexate, azathioprine, and rituximab. After 2 months of treatment with anifrolumab, the patient still exhibited extensive postinflammatory hyperpigmentation and scarring, but experienced dramatic improvement in disease activity with reduced erythema and scaling (D-F). After 6 months of treatment with anifrolumab, prednisone was successfully weaned from 10 mg to 2 mg daily.
See this image and copyright information in PMC

References

    1. Wahie S, Daly AK, Cordell HJ, et al. Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Invest Dermatol. 2011;131(10):1981-1986. doi: 10.1038/jid.2011.167 - DOI - PubMed
    1. Sprow G, Dan J, Merola JF, Werth VP. Emerging therapies in cutaneous lupus erythematosus. Front Med (Lausanne). 2022;9:968323. doi: 10.3389/fmed.2022.968323 - DOI - PMC - PubMed
    1. Morand EF, Furie R, Tanaka Y, et al. ; TULIP-2 Trial Investigators . Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211-221. doi: 10.1056/NEJMoa1912196 - DOI - PubMed
    1. Blum FR, Sampath AJ, Foulke GT. Anifrolumab for treatment of refractory cutaneous lupus erythematosus. Clin Exp Dermatol. 2022;47(11):1998-2001. doi: 10.1111/ced.15335 - DOI - PubMed
    1. Rönnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol. 2011;23(2):113-121. doi: 10.1016/j.smim.2011.01.009 - DOI - PubMed

MeSH terms

Substances